NVO—FDA extends review of IdegLira by three months; PDUFA date now in Dec 2016: http://www.novonordisk.com/media/news-details.2039453.html So, both NVO’s IdegLira and SNY’s competing IGlarLixi (#msg-124682017) have their PDUFA dates extended by three months.